Oxford Nanopore Technologies plc (LSE:ONT), the Oxford-based developer of nanopore DNA and RNA sequencing devices, has spent most of its life on the London Stock Exchange's Main Market asking shareholders to accept heavy losses as the price of building a new sequencing platform. Its interim results, published on 19 August 2026, offered the FTSE 250 company's clearest evidence yet that the arithmetic is changing.
Revenue for the six months to 30 June 2026 rose 12.3% at constant currency to £116.7m, gross Margin climbed 400 basis points to 62.2% and the adjusted EBITDA loss more than halved to £22.1m. With a new chief executive six months into the job, a $20m licensing fee due in the second half and a target of adjusted EBITDA breakeven in FY27, the question for 2026 is whether Oxford Nanopore can keep growing while shrinking its cash burn.
Interim results: losses halve as margins improve and guidance is reshaped
The 19 August 2026 interim statement showed H1 2026 Revenue of £116.7m, up 10.5% on a reported basis from £105.6m. Gross Profit rose 18.2% to £72.6m, lifting gross margin from 58.2% to 62.2%. The adjusted EBITDA loss narrowed to £22.1m from £48.3m, the operating loss shrank to £50.7m from £77.8m, and the loss for the period fell to £48.0m from £71.8m, or 4.9p per share against 7.5p.
Adjusted operating costs fell 6.9% year on year after restructuring in 2025. Chief executive Francis Van Parys, who took over from founder Dr Gordon Sanghera on 2 March 2026, said: "We delivered strong financial progress, with gross margin increasing by 400 basis points to 62.2% and the adjusted EBITDA loss more than halving year-on-year to £22.1 million." The results, he added, "show that we are tracking well towards adjusted EBITDA breakeven in FY27."
Guidance for FY26 was restated. The company now expects constant-currency revenue growth of 16% to 20% excluding a $20m one-off fee from a new cross-licensing agreement with an unnamed "global diagnostics company", or roughly 23% to 27% including it. At the annual results on 2 March 2026 the guidance had been 21% to 25%, so the underlying range has come down even as the headline range has moved up. Adjusted operating costs are now expected to fall by up to 2% rather than grow by 0% to 5%. The licensing deal also brings $15m of committed product purchases over FY27 and FY28 plus ongoing royalties.
On 25 August 2026 the company named David Miller, formerly of Pacific Biosciences and Illumina, as chief development and product officer from 1 September, alongside a new chief Marketing and communications officer joining in October.
What Oxford Nanopore does
Oxford Nanopore sells sequencing instruments and the consumable flow cells and kits that run on them. Its technology reads DNA and RNA by passing strands through protein nanopores, producing long reads in real time. The portable MinION sits at the entry level and the high-throughput PromethION range targets population-scale and clinical genomics. PromethION generated £59.1m of revenue in H1 2026, up 15.7%, while MinION brought in £28.8m and kits and services £28.9m.
Research customers remain the largest end market at £76.0m, or 65.1% of H1 2026 revenue, but clinical is growing fastest, up 35.4% to £17.6m, helped by the NHS metagenomics network, which expanded to 18 sites in the half. Applied industrial customers contributed £13.7m and biopharma £9.5m, the latter up 25.0% on mRNA quality-control work, including a GMP workflow launched with Lonza. EMEAI produced £55.6m, the Americas £39.1m and Asia-Pacific £22.0m, with customers in more than 125 countries.
Partnerships are central to the strategy: an expanded collaboration with Danaher's Cepheid on infectious-disease workflows, a tuberculosis assay with bioMérieux on the GridION Dx, the company's first CE and UKCA-marked in vitro diagnostic device, and post-period agreements with Agilent and with Natera's MyOme.
Full-year 2025: revenue up 22% but cash falls by a quarter
The annual results published on 2 March 2026 showed FY25 revenue of £223.9m, up 22.2% reported and 24.2% at constant currency. Gross margin improved to 58.6% from 57.5%. The adjusted EBITDA loss narrowed to £86.7m from £117.9m, although the operating loss widened slightly to £155.3m after £22.6m of restructuring costs covering 138 Job losses and the discontinuation of the ElysION platform and P2 Solo device. Loss before tax was £139.9m and loss per share 15.1p.
Cash and liquid investments fell 25.0% to £302.8m at 31 December 2025, and to £234.5m by 30 June 2026 after a £68.3m decline in the half, including a £42.8m operating cash outflow and £24.5m of capitalised development spending. The company does not pay a Dividend and targets positive free Cash Flow only in FY28.
What could move the shares next
The $20m licensing fee will land in H2, and the company's practice of issuing a full-year trading update in January means investors should learn early in 2027 whether the 16% to 20% underlying growth range was met. Delivery of the PromethION Plus flow cell, designed to raise output without extra wash and reload steps, and clinical uptake of the GridION Dx are the product milestones to track.
Beyond that, the roadmap is explicit: adjusted EBITDA breakeven in FY27, positive free cash flow in FY28 and, by 2030, revenue above $700m with an adjusted EBITDA margin over 15%. Litigation is another marker: MGI Australia has conceded infringement of four Australian patents, with trial scheduled for 2027, and UK High Court proceedings against MGI and BGI entities are ongoing.
Risks investors should watch
Oxford Nanopore is still loss-making and consuming cash. Liquid resources of £234.5m at June 2026 compare with a first-half outflow of £68.3m, leaving little room for slippage on the breakeven timetable, and the company regularly issues new shares, as its 1 September 2026 Equity announcement shows.
Demand is uneven. Revenue in China fell 15.7% in H1 2026 because of tighter export controls, dragging Asia-Pacific down 8.4% at constant currency, while the Americas were held back by grant-funding and procurement constraints at academic and government accounts. Research customers still generate almost two thirds of revenue, so pressure on public science budgets matters. Competition from Illumina, Pacific Biosciences and MGI is intense, and lawsuits are costly and uncertain. According to lse.co.uk data, the shares traded between a 52-week low of 95.70p on 13 July 2026 and a high of 191.40p on 27 August 2026, a reminder of how volatile the stock can be.
Outlook
Oxford Nanopore enters the second half of 2026 with a lower cost base, improving margins and a new management team, but also with softer underlying growth guidance than in March and a shrinking cash pile. The FY27 breakeven target is now the yardstick for every update. Investors should watch the full-year trading update, the pace of clinical and biopharma growth, China and US academic demand, and the cash position at 31 December 2026. The strategic story is intact; it now simply comes with a nearer deadline.






Please wait processing your request...